A combination of amantadineþoseltamivir as well as
favirpiravirþoseltamivir have demonstrated enhanced drug effi
cacy in H5N1 infected mice. Recently, combination therapy with
three antiviral drugs (amantadine, ribavirin, and oseltamivir) in
patients with severe A/H1N1 2009 (pH1N1) influenza in Korea has
reduced the 14-day mortality. In another study, triple-combination
antiviral drug therapy showed similar pharmacokinetics to mono-drug
therapy and demonstrated increased safety in immunocompromised
patients. Currently, several combination therapies based on
approved and/or new drugs are under investigation.